WO2013122343A1 - 백합나무 수피에서 위장 질환 치료 성분을 추출하는 방법 - Google Patents
백합나무 수피에서 위장 질환 치료 성분을 추출하는 방법 Download PDFInfo
- Publication number
- WO2013122343A1 WO2013122343A1 PCT/KR2013/000817 KR2013000817W WO2013122343A1 WO 2013122343 A1 WO2013122343 A1 WO 2013122343A1 KR 2013000817 W KR2013000817 W KR 2013000817W WO 2013122343 A1 WO2013122343 A1 WO 2013122343A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- extract
- bark
- lily
- bark extract
- dried
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/57—Magnoliaceae (Magnolia family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
Definitions
- the present invention is a method for extracting a gastrointestinal disease therapeutic ingredient containing epituripinolide and Costunolide as active ingredients in bark of bark and Epiturpinolide and course extracted by the method Tunolide (Costunolide) relates to a gastrointestinal disease treatment.
- Gastritis and gastric ulcers are the most frequent diseases of the digestive system, with about 10% of Korea's population experiencing at least once in their lifetime.
- the gastric wall (gastric wall is composed of mucosal layer, submucosa, muscle layer, and membrane) is located in the stomach acid.
- gastritis is a state in which the mucosa is damaged
- gastric ulcer is a case in which the submucosa or muscle layer is damaged.
- the cause of gastritis and gastric ulcers is known to be caused by the imbalance between the attack and defense factors, that is, the increase of the attack factors or the weakening of the defense factors.
- Factors that increase the attack factor include increased acid and pepsin secretion.
- Factors that weaken the defense factor include deficits in the structure and form of the gastric mucosa, decreased mucus secretion, decreased bicarbonate ion secretion, and decreased prostaglandin production. For example, it is known that gastric ulcers are also caused by infection of Helicobacter pylori.
- gastric ulcer development is the excessive secretion of gastric acid, which is a hydrochloric acid secreted by gastric wall cells, which activates pepsin to decompose proteins as well as lethal action on damaged gastric walls.
- gastric acid which is a hydrochloric acid secreted by gastric wall cells, which activates pepsin to decompose proteins as well as lethal action on damaged gastric walls.
- Currently used therapeutic agents for gastritis and gastric ulcer are classified into drugs that inhibit attack factors such as gastric acid, pepsin, smoking, oxygen free radicals, and alcohol, and drugs that enhance defense factors according to pathophysiology.
- Attack inhibitors include gastric acid secretion inhibitors such as antacids, H2 receptor antagonists (Cimetidine, Ranitidine, Famotidine, etc.), and Proton pump inhibitors (PPI: Omeprazole, Lansoprazole, etc.).
- gastric acid secretion inhibitors such as antacids, H2 receptor antagonists (Cimetidine, Ranitidine, Famotidine, etc.)
- PPI Proton pump inhibitors
- Protective agent enhancers protect the gastric mucosa by inducing ulcer lesion coating, promoting mucus synthesis and secretion, increasing gastric mucosa, increasing endogenous prostaglandin, and increasing tissue regeneration, depending on the type of protective factor enhancer. There is a mechanism of action and these are known to be particularly useful in preventing ulcer recurrence. H. Pylori eradication therapy is also considered as one of the anti-ulcer drug treatments.
- gastritis and gastric ulcers are caused by a variety of complex causes, and the cause of the disease is still not clearly identified, and thus, there is no absolute method for the treatment.
- Liriodendron tulipifera L. (Yellow-popular) is a deciduous broad-leaved tree belonging to Magnoliaceae, and has been mainly used as a pulp solvent or wood timber. Extracts of wood, bark and leaves of the lily tree contain alkaloids, seskitelpenes and lignan compounds.
- the bark of the yellow-poplar bark has an antimicrobial apolphine alkaloid (Hufford CD and Funderburk MJ, J. Pharm. Sci. 63: 1338-1339,1974; Hufford CD et al., J. Pharm. Sci. 64: 789-792 , 1975).
- Alkaloid-containing lily bark extracts have been used to treat malaria during the American Revolution, and alkaloids, glaucine, have been used as antitussives in the Soviet Union.
- the herbaceous bark is called “American cabbage” and is used for relieving asthma. According to a 1975 study, the alkaloid fraction of the lily tree was antibacterial. Other alkaloids such as N-methyllaurotetanine, lirioferine and liriotulipiferine have antibacterial activity against fungi (Huang Hsu, CY, 1976. MS thesis , North Carlolina State University, Raleigh). In addition, dehydroglaucine and liriodenine, which are known to be cytotoxic, have antimicrobial activity. (Warthen D, Gooden EL and Jacobson M. 1969, J. Pharm. Sci., 58: 637-638, Hufford CD, Funderburk MJ, Morgan J M. et al. 1975, J. Pharm. Sci., 64: 789- 792, Chen CR, Bed JL, Doskotch RW et al., 1974, Lloydia 37: 493-500).
- Lily extract contains sesquiterpene lactones with antitumor activity. Costunolide, tulipinolide, epipitulipinolide, epitulipdienolide, and gamma-liriodenolide. (Doskotch R. W and EL-Feraly FS, J Pharm. Sci. 58: 877-880, 1969; Doskotch R. W and E LI-Feraly FS, J. Org. Chem. 35: 1928-1936, 1970; Moon MK et al. Arch. Pharm. Res. 30: 299-302, 2007).
- the related compounds include lipiferolide, epituripinolide diepoxide and peroxyferolide as related compounds.
- the bark has a lignan based material (Dickey E E. 1958, J. Org. Chem. 23: 179-184, Fujimoto H and Higuchi T., 1977, J. Jap. Wood Res. Soc, 23: 405 -410).
- Liriodendrin has been reported to promote antithrombosis (Japanese patent) and bone growth in animals (Korean Patent Registration No. 10-0597563).
- the inventors have conducted a variety of experiments confirmed that the epiturinoids and costuolides extracted from the bark of lily tree have an excellent therapeutic effect on the healing of gastritis and peptic ulcers, the extract of the bark of the lily bark And it was confirmed that a variety of trace components exist in addition to costunolide.
- the present inventors continue to research to maximize the therapeutic effect and minimize side effects in using the lily bark extract as a prophylactic or therapeutic agent of gastrointestinal diseases, to produce an extract showing an excellent therapeutic effect from the bark of the bark
- the present invention has been completed.
- the technical problem to be achieved by the present invention is to use the bark extract as a preventive or therapeutic agent for gastrointestinal diseases as a result of continuing the research to maximize the therapeutic effect and minimize side effects, extracts showing excellent therapeutic effect from the bark of the bark It is intended to develop an efficient way to manufacture the.
- An object of the present invention is to 1) mix 2 to 20 parts by weight of ethyl acetate or dichloromethane with respect to 1 part by weight of shredded bark; 2) extracting and concentrating the mixture in a range of 15 to 50 ° C. for 1 to 4 days; wherein the bark extract comprises 0.1 to 10% by weight of epiturinoid and costunide
- the extraction is to provide a method for producing a lily bark extract, characterized in that the extraction by cold needle, percolation, ultrasonic, warm needle or reflux method.
- Still another object of the present invention is to 1) dissolving the lily bark extract obtained above in an aqueous solution of C1-C3 lower alcohol; 2) mixing hexane by adding hexane to the mixed solution, and then removing the oil-containing components and insoluble substances in the hexane layer; And 3) separating and purifying the lower alcohol aqueous solution layer.
- step 2 water is added to the lower alcohol aqueous solution layer obtained in step 2) to prepare a lower concentration aqueous alcohol solution, and further comprising the step of separating and purifying the dichloromethane layer by adding dichloromethane.
- another object of the present invention is a pharmaceutical composition for treating or preventing gastrointestinal diseases such as gastritis or gastric ulcer, which contains a lily bark extract as an active ingredient, as an active ingredient of the lily bark extract, epiturinolipides and cos It is to provide a pharmaceutical composition characterized in that it contains a tunolide.
- the effect of the present invention is to use the extract bark extract as a preventive or therapeutic agent for gastrointestinal diseases to maximize the therapeutic effect and to minimize the side effects, as a result, to produce an extract showing an excellent therapeutic effect from the bark of the bark To provide an efficient method.
- Figure 1 shows the liquid chromatograph of the obtained product obtained by extracting the extract of the bark of the lily tree obtained in Preparation Example 9 to confirm the presence of epiturifinoride, costunolide.
- Figure 2 shows the liquid chromatograph of the lily bark extract obtained in Preparation Example 1 confirming the presence of epiturifinoride, costunolide of the extract before the purification separation process.
- Figure 3 shows the liquid chromatograph of the obtained product obtained by extracting the lily bark extract obtained in Preparation Example 11 to confirm the presence of epiturifinoride, costunolide.
- the present invention provides an extract of the bark of lily of the valley containing epituripine and costuinolide.
- the present invention also provides a method for producing the lily bark extract.
- the present invention provides a pharmaceutical composition for treating or preventing gastrointestinal diseases containing the lily bark extract or the same as an active ingredient and an oral preparation containing the same.
- the lily bark extract of the present invention can extract the lily bark with ethyl acetate, dichloromethane, alcohol, an aqueous alcohol solution or a mixture thereof.
- the extract contains epituripine and costuride as active ingredients.
- the extract of the bark of the present invention has various pharmacological components, and representative indicator components include epituripine and costunide.
- Lily bark extract of the present invention has an excellent effect on gastrointestinal diseases.
- various test models such as a submerged stress gastric ulcer model, hydrochloric acid-ethanol (HCl-EtOH) gastritis model, indomethacin gastric ulcer model, In addition to inhibiting gastritis and gastric ulcers, prostaglandin biosynthesis was promoted.
- the present invention provides a pharmaceutical composition for treating or preventing gastrointestinal diseases, which contains epiturifinoriide and costunide, which are one of the components of the bark extract, as active ingredients.
- the present invention provides a pharmaceutical composition for treating or preventing gastrointestinal diseases containing the lily bark extract as an active ingredient.
- the gastrointestinal disease is preferably gastritis or gastric ulcer.
- the present invention (1) a method of extracting the bark of the lily of the valley using ethyl acetate or dichloromethane as a specific solvent (method 1), (2) purifying the extract obtained in the step (1) to improve the content of the indicator components It provides a method for producing a lily bark extract, including a purification method (Method 2) to prepare a higher extract.
- the lily bark is cut and concentrated, and then extracted and concentrated with an extraction solvent to prepare an extract of the bark of the lily tree containing epiturifinorides and costunides.
- the extraction solvent is characterized in that it is selected from dichloromethane or ethyl acetate and the bark of the lily is preferably used dry.
- the aqueous solution and hexane are added to the extract obtained in Method 1 to remove the oil-soluble component and the water-insoluble substance dissolved in the hexane layer, and then the alcohol aqueous solution layer is separated to obtain the epitury finide of the present invention. And is purified to separate the high cost of cous noride. If necessary, water may be added to the aqueous solution of alcohol to form a low concentration of aqueous solution of alcohol, and then fractionated into dichloromethane to separate and purify the epiturifinorides and costunolides dissolved in the dichloromethane layer with higher purity.
- the extract or fraction layer of Method 1 or Method 2 is sufficiently concentrated and dried to remove residual solvent to complete the extract of the present invention.
- the present invention is a manufacturing method that can efficiently extract or purify the epiturifinoriide (Formula 1) and Costunolide (Formula 2) content of the bark extract of the lily bark.
- Lily bark used in the preparation of the present invention was collected from the per second forest located in Gangjin-gun, Jeollanam-do, Korea.
- the extracted bark was dried, chopped or dried, and then extracted by extracting at 2 to 20 times, preferably 4 to 10 times the amount of the extraction solvent for 24 to 96 hours at 15 to 50 ° C under reduced pressure. Concentration and drying yielded the extract of the present invention.
- the prepared bark extract was confirmed by the high performance liquid chromatography method using the Agilent HPLC 1200 series (U.S.A.) equipment to determine the presence of epiturifinoride and costunolide and the content was measured. Analytical conditions were measured at an ultraviolet wavelength of 215 nm with a sample concentration of 5 mg / mL using a reverse phase column Kromasil C18 column (flow rate: 1.0 ml / min), and gradient conditions of water and methanol were used as mobile phases (Table 1). .
- epiturifinoride and costunolide were detected in about 31 minutes and about 36 minutes, respectively.
- the presence of epiturinoid and costunide is the retention time required after the purchase of a standard of epiturinoid and costunide and the injection of both samples into high performance liquid chromatography. ) Were confirmed to coincide with each other.
- the molecular weight of each component including epituripine and costurinide, was investigated for the lily extract of LC.
- the molecular weight of epiturifinoride was 290, and the molecular weight of costunolide was 232.
- the instrument used for LC-MS analysis was performed using Waters' LC-MS analysis instrument, and the analysis conditions were reverse phase column. Sample concentration volume was analyzed at 2 microliters, flow rate 0.3mL / min, PDA ultraviolet wavelength was measured at 200 ⁇ 500nm. Detailed HPLC mobile phase gradient conditions are shown in Table 2.
- the present invention provides a method (method 1) of the extract of the bark of the lily-bearing tree containing epitrilipinide and costunoid.
- Method 1 of the present invention comprises the steps of 1) mixing 2 to 20 parts by weight of ethyl acetate or dichloromethane with respect to 1 part by weight of shredded yellow bark; And 2) extracting and condensing the mixture of the bark extract in a range of 15 to 50 ° C. for 1 to 4 days.
- the bark extract contains 0.1 to 10% by weight of epituripine and costuinolide, and the extraction is characterized in that the extraction by cold, percolation, ultrasonic, warm or reflux method.
- Preparation Examples 1 to 8 below show a method for producing a lily bark extract according to Method 1 of the present invention.
- the content of epiturinoidide was in the range of 3.1 wt% to 9.7 wt%, and the costunide content was 0.14 wt% to 0.35 wt%.
- Preparation Example 1 to Preparation Example 6 below shows a method of preparing a lily bark extract compared to Method 1 of the present invention. Therefore, in Comparative Examples 1 to 6, the content of epiturinoidide was in the range of 1.28 wt% to 1.97 wt%, and the costunide content was 0.08 wt% to 0.18 wt%, relative to Method 1 of the present invention. Low content.
- the lily bark extract prepared according to the method of Preparation Example showed a high epiturifinoride content of 3.1% to 9.7%.
- the extract of the bark of the yellow bark prepared according to the Comparative Preparation Method showed a low content of epiturifinorides of 1.28% to 1.97%. This is based on the difference of the extraction solvent, it was confirmed that the extract extracted with ethyl acetate and dichloromethane is better than the extract extracted with an alcoholic solvent such as ethanol, isopropanol or butanol.
- the present invention also provides a purification method (method 2) for preparing the above components at high concentration.
- Method 2 of the present invention comprises the steps of 1) dissolving the extract of the bark of the yellow bark obtained in Method 1 with an aqueous solution of C1-C3 lower alcohol; 2) mixing hexane by adding hexane to the mixed solution, and then removing the oil-containing components and insoluble substances in the hexane layer; And 3) separating and purifying the lower alcohol aqueous solution layer.
- the method may further include separating and purifying the dichloromethane layer by adding dichloromethane.
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
retention time (분) | 물 (%) | 메탄올 (%) |
0 | 98 | 2 |
10 | 50 | 50 |
60 | 0 | 100 |
70 | 0 | 100 |
80 | 98 | 2 |
분 | 물 (%) | ACN (%) |
0 | 85 | 15 |
10 | 30 | 70 |
60 | 0 | 100 |
70 | 0 | 100 |
에피튜리피노라이드 | 코스튜노라이드 | |
제조실시예 1 | 3.96% | 0.18% |
제조실시예 2 | 3.94% | 0.14% |
제조실시예 3 | 3.19% | 0.19% |
제조실시예 4 | 3.96% | 0.20% |
제조실시예 5 | 4.48% | 0.27% |
제조실시예 6 | 5.10% | 0.35% |
제조실시예 7 | 9.11% | 0.29% |
제조실시예 8 | 9.65% | 0.31% |
제조비교예 1 | 1.28% | 0.08% |
제조비교예 2 | 1.63% | 0.15% |
제조비교예 3 | 1.75% | 0.10% |
제조비교예 4 | 1.97% | 0.17% |
제조비교예 5 | 1.80% | 0.13% |
제조비교예 6 | 1.57% | 0.17% |
에피튜리피노라이드 | 코스튜노라이드 | |
제조실시예 9 | 9.72% | 0.28% |
제조실시예 10 | 10.94% | 0.30% |
제조실시예 11 | 23.43% | 0.79% |
제조실시예 12 | 21.19% | 0.94% |
Claims (5)
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13749032.2A EP2815758A4 (en) | 2012-02-16 | 2013-02-01 | PROCESS FOR EXTRACTING TREATMENT INGREDIENTS FOR GASTRO-INSTESTIAN DISEASES, SUCH INGREDIENTS FROM THE LIRIODENDRON TULIPIFERA BARK |
CN201380009736.9A CN104125835A (zh) | 2012-02-16 | 2013-02-01 | 从北美鹅掌楸树皮中提取胃肠道疾病治疗成分的方法 |
US14/379,165 US9283205B2 (en) | 2012-02-16 | 2013-02-01 | Method for extracting treatment ingredients for gastrointestinal diseases from bark of liriodendron tulipifera |
JP2014557560A JP2015507005A (ja) | 2012-02-16 | 2013-02-01 | ユリノキの樹皮から胃腸疾患の治療成分を抽出する方法 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20120015710A KR101353306B1 (ko) | 2012-02-16 | 2012-02-16 | 백합나무 수피에서 위장 질환 치료 성분을 추출하는 방법 |
KR10-2012-0015710 | 2012-02-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2013122343A1 true WO2013122343A1 (ko) | 2013-08-22 |
Family
ID=48984421
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2013/000817 WO2013122343A1 (ko) | 2012-02-16 | 2013-02-01 | 백합나무 수피에서 위장 질환 치료 성분을 추출하는 방법 |
Country Status (6)
Country | Link |
---|---|
US (1) | US9283205B2 (ko) |
EP (1) | EP2815758A4 (ko) |
JP (1) | JP2015507005A (ko) |
KR (1) | KR101353306B1 (ko) |
CN (1) | CN104125835A (ko) |
WO (1) | WO2013122343A1 (ko) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4093717A (en) * | 1975-07-16 | 1978-06-06 | University Of Mississippi | Antimicrobial compositions |
KR20000066932A (ko) * | 1999-04-22 | 2000-11-15 | 박호군 | 세스퀴테르펜 락톤 화합물 코스투놀라이드의 염증질환 치료제로서의 용도 |
KR20050055856A (ko) * | 2003-12-09 | 2005-06-14 | 한국생명공학연구원 | 코스투놀라이드를 함유하는 에이피-1 저해제 |
KR100597563B1 (ko) | 2004-04-28 | 2006-07-06 | 임강현 | 골성장촉진활성을 갖는 엘루테로사이드 e 를 함유하는 건강기능식품 |
KR20100036052A (ko) * | 2008-09-29 | 2010-04-07 | 서울대학교산학협력단 | 월계수 잎의 단일성분 추출물을 함유한 파킨슨병과 퇴행성 신경계 뇌질환의 예방 및 치료용 조성물 |
KR20110091137A (ko) * | 2010-02-05 | 2011-08-11 | 주식회사 코리아나화장품 | 백합나무 추출물을 유효성분으로 함유하는 화장료 조성물 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2580733A1 (en) | 2003-09-20 | 2005-04-07 | Glykon Technologies Group, Llc | (-)-hydroxycitric acid for delaying gastric emptying |
CN101073590B (zh) * | 2007-06-18 | 2010-06-09 | 石任兵 | 木香总内酯提取物及其制备方法 |
KR101187792B1 (ko) | 2010-02-05 | 2012-10-11 | 김승헌 | 풍력 발전용 날개 조립체 |
CN102335233B (zh) * | 2011-08-08 | 2013-08-07 | 南京林业大学 | 一种鹅掌楸的多酚类提取物及其提取方法和应用 |
KR101346066B1 (ko) | 2012-02-16 | 2013-12-31 | 초당약품공업 주식회사 | 백합나무 수피 추출물을 유효 성분으로 함유하는 약학적 조성물 |
KR101327282B1 (ko) * | 2012-02-16 | 2013-11-08 | 초당약품공업 주식회사 | 백합나무 수피 추출물을 유효 성분으로 함유하는 개선된 의약 제형 |
-
2012
- 2012-02-16 KR KR20120015710A patent/KR101353306B1/ko active IP Right Grant
-
2013
- 2013-02-01 JP JP2014557560A patent/JP2015507005A/ja not_active Withdrawn
- 2013-02-01 EP EP13749032.2A patent/EP2815758A4/en not_active Withdrawn
- 2013-02-01 CN CN201380009736.9A patent/CN104125835A/zh active Pending
- 2013-02-01 US US14/379,165 patent/US9283205B2/en not_active Expired - Fee Related
- 2013-02-01 WO PCT/KR2013/000817 patent/WO2013122343A1/ko active Application Filing
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4093717A (en) * | 1975-07-16 | 1978-06-06 | University Of Mississippi | Antimicrobial compositions |
KR20000066932A (ko) * | 1999-04-22 | 2000-11-15 | 박호군 | 세스퀴테르펜 락톤 화합물 코스투놀라이드의 염증질환 치료제로서의 용도 |
KR20050055856A (ko) * | 2003-12-09 | 2005-06-14 | 한국생명공학연구원 | 코스투놀라이드를 함유하는 에이피-1 저해제 |
KR100597563B1 (ko) | 2004-04-28 | 2006-07-06 | 임강현 | 골성장촉진활성을 갖는 엘루테로사이드 e 를 함유하는 건강기능식품 |
KR20100036052A (ko) * | 2008-09-29 | 2010-04-07 | 서울대학교산학협력단 | 월계수 잎의 단일성분 추출물을 함유한 파킨슨병과 퇴행성 신경계 뇌질환의 예방 및 치료용 조성물 |
KR20110091137A (ko) * | 2010-02-05 | 2011-08-11 | 주식회사 코리아나화장품 | 백합나무 추출물을 유효성분으로 함유하는 화장료 조성물 |
Non-Patent Citations (15)
Title |
---|
CHEN C R; BED J L; DOSKOTCH R W ET AL., LLOYDIA, vol. 37, 1974, pages 493 - 500 |
DICKEY E E., J. ORG. CHEM., vol. 23, 1958, pages 179 - 184 |
DOSKOCH R W; EL-FERALY F S; FAIRCHILD E H, J. CHEM. SOC (CHEM. COMM), 1976, pages 402 - 403 |
DOSKOTCH R W; EL-FERALY F S; FAIRCHILD E H, J. ORG. CHEM., vol. 42, 1977, pages 3614 - 3618 |
DOSKOTCH R. W; E LI-FERALY F. S., J. ORG. CHEM., vol. 35, 1970, pages 1928 - 1936 |
DOSKOTCH R. W; EL-FERALY F. S., J PHARM. SCI., vol. 58, 1969, pages 877 - 880 |
DOSKOTCH, R. W. ET AL.: "New sesquiterpene lactones from Liriodendron tulipifera", PHYTOCHEMISTRY, vol. 14, no. 3, 1975, pages 769 - 773, XP003031295 * |
FUJIMOTO H; HIGUCHI T., J. JAP. WOOD RES. SOC, vol. 23, 1977, pages 405 - 410 |
HUANG HSU, C-Y, MS THESIS, 1976 |
HUFFORD C D; FUNDERBURK M J; MORGAN J M. ET AL., J. PHARM. SCI., vol. 64, 1975, pages 789 - 792 |
HUFFORD C. D. ET AL., J. PHARM. SCI., vol. 64, 1975, pages 789 - 792 |
HUFFORD C. D.; FUNDERBURK M. J., J. PHARM. SCI., vol. 63, 1974, pages 1338 - 1339 |
MOON M. K. ET AL., ARCH. PHARM .RES., vol. 30, 2007, pages 299 - 302 |
See also references of EP2815758A4 * |
WARTHEN D; GOODEN E L; JACOBSON M., J. PHARM. SCI., vol. 58, 1969, pages 637 - 638 |
Also Published As
Publication number | Publication date |
---|---|
EP2815758A1 (en) | 2014-12-24 |
KR20130094456A (ko) | 2013-08-26 |
CN104125835A (zh) | 2014-10-29 |
US9283205B2 (en) | 2016-03-15 |
EP2815758A4 (en) | 2015-08-12 |
KR101353306B1 (ko) | 2014-01-21 |
JP2015507005A (ja) | 2015-03-05 |
US20150011624A1 (en) | 2015-01-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2015183027A1 (ko) | 황칠 나무 추출물을 함유하는 간 기능 개선용 조성물 | |
WO2013172640A1 (ko) | 두충으로부터 분리된 화합물을 포함하는 열충격단백질 유도 활성을 갖는 조성물 | |
WO2009148279A2 (ko) | 바이러스 억제제로서 유용한 트리테르페노이드계 화합물 | |
WO2013147419A1 (en) | A composition comprising the compound isolated from chrysanthemum indicum for treating or preventing cerebrovascular system involved anxiety and the use thereof | |
WO2013122344A1 (ko) | 백합나무 수피 추출물을 유효 성분으로 함유하는 약학적 조성물 | |
WO2010117194A2 (ko) | 지방산 계열 화합물을 유효성분으로 함유하는 위장 질환 예방 또는 치료용 조성물 | |
WO2013122345A1 (ko) | 백합나무 수피 추출물을 유효 성분으로 함유하는 개선된 의약 제형 | |
WO2018212531A1 (ko) | 퉁퉁마디 추출물을 포함하는 치매 예방 또는 치료 및 인지기능 개선용 약제학적 조성물 | |
WO2020071630A1 (ko) | 천연소재 추출물을 포함하는 피부 개선용 조성물 | |
WO2013122343A1 (ko) | 백합나무 수피에서 위장 질환 치료 성분을 추출하는 방법 | |
WO2022139529A1 (en) | Composition for preventing, improving or treating gastritis or peptic ulcer comprising extract of cinnamomum cassia, fraction of said extract, isolate of said fraction or compounds isolated therefrom | |
WO2015108323A1 (ko) | 유해물질의 함량을 저감시킨 위장질환 치료용 애엽 추출물의 제조방법 | |
WO2014042426A1 (ko) | 사이코사포닌 a, 베르베린 및 리코이소플라본 b를 포함하는 위장질환의 예방 또는 치료용 조성물 | |
WO2009148280A2 (ko) | 바이러스 억제제로서 유용한 디아릴 헤파토노이드계 화합물 | |
WO2014069801A1 (ko) | 세스퀴터핀 락톤계 위장 질환 치료용 의약 조성물 | |
WO2021150076A1 (ko) | 만성폐쇄성 폐질환의 예방 또는 치료용 약학적 조성물 또는 건강기능식품 | |
WO2014175650A1 (ko) | 백합나무 수피에서 만성 골수성 백혈병 치료 성분을 추출 분리하는 방법 | |
WO2018101798A1 (ko) | 인진쑥 수용성 추출물, 그 용도 및 제조 방법 | |
WO2012033329A2 (ko) | 미나리 추출물을 유효성분으로 함유하는 학습능력 또는 기억력 장애 예방 또는 치료용 조성물 및 그 제조방법 | |
WO2011046411A2 (ko) | 뇌신경 세포 보호 활성 및 아세틸콜린에스테라제 저해 활성을 갖는 율피 추출물 및 그의 용도 | |
WO2010036065A9 (ko) | 낙석등 건조 추출물의 에틸아세테이트 분획물을 유효성분으로 함유하는 염증성 질환 예방 및 치료용 약제학적 조성물과 상기 분획물의 제조방법 | |
WO2016175589A2 (ko) | 혼합 생약 추출물을 함유하는 호흡기 질환 예방 또는 치료용 약학적 조성물 | |
WO2014178617A1 (en) | Oral formulation comprising extract of coptis rhizome having masked bitter taste | |
WO2013191342A1 (ko) | 독성물질을 제거한 삼백초 정제물 및 분획물의 제조방법 및 상기 정제물을 유효성분으로 함유하는 천식 및 알러지성 질환의 치료 및 예방을 위한 조성물 | |
WO2014069799A1 (ko) | 세스퀴터핀 락톤계 위장 질환 치료용 의약 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13749032 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2014557560 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14379165 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REEP | Request for entry into the european phase |
Ref document number: 2013749032 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2013749032 Country of ref document: EP |